janet woodcock, md | fda cder re-organization and impact on rare diseases
Published 5 years ago • 177 plays • Length 25:53Download video MP4
Download video MP3
Similar videos
-
6:35
janet woodcock, director cder fda on nord registry program
-
1:34
cder's janet woodcock discusses the future of drug development
-
1:15
janet woodcock - fda and gene therapy
-
2:01
janet woodcock - patients, clinical trials, and the fda
-
1:14
janet woodcock - fda and gene therapy
-
1:44:40
tb care in south africa's private sector
-
4:28
sen. warren presses fda to protect consumers from unintentional prescription overdoses
-
31:46
case study on quality culture on the shop floor (opportunities and challenges)
-
2:21
fda's janet woodcock provides advice to patient advocates
-
16:43
fda’s dr. janet woodcock | rare disease treatments: regulatory & policy reform
-
1:34
dr. janet maynard recognizes successes and continued need for rare disease research grants
-
18:56
interview with janet woodcock | fda center for drug evaluation
-
1:37:35
2022 rare disease week - rare disease congressional caucus briefing
-
0:59
patient focused drug development and the fda
-
1:16:01
rare disease congressional caucus briefing - september 14, 2023
-
12:38
telehealth and the rare disease community
-
1:25
janet woodcock - nord summit presentation
-
23:45
cder director dr. janet woodcock’s plenary address at the 2014 pda/fda joint regulatory conference
-
12:01
2018 annual meeting - afternoon keynote with dr. janet woodcock
-
11:49
janet woodcock, fda, on future innovation in drug development
-
21:49
2013 pda fda - janet woodcock md
-
0:45
janet woodcock on mortality data